

40th

Annual General Meeting


CHAIRPERSON'S SPEECH

Kiran Mazumdar-Shaw
Chairperson & Managing Director

July 27th, 2018
Biocon Research Centre

BSE: 532523 | NSE: BIOCON | REUTERS: BION.NS
| BLOOMBERG: BIOS IN | WWW.BIOCON.COM

Enduring
Edge



Welcome



2018 marks **40 years** of **Biocon's Journey of Endurance**

Ogivri™

- **1st** Biosimilar Trastuzumab approved in **U.S.**
- **1st** Biosimilar from India approved by **U.S. FDA**
- **1st** Biosimilar from **Biocon-Mylan joint portfolio** approved in **U.S.**

Outcome of commitment and perseverance of thousands of Bioconites



Semglee™

- **1st biosimilar** from Biocon-Mylan joint portfolio approved by **European Commission**
- Approved by **TGA, Australia**
- Approved in **Russia, South Korea**



2009

Launched in India

2010-12

Global PK/PD
Study

2013-15

Global INSTRIDE
Clinical Studies

2016-17

Launched in Japan,
UAE, Malaysia

2018

Approved in
EU

Fulphila™

- **1st** biosimilar Pegfilgrastim approved and launched in **U.S.**
- **2nd** biosimilar from Biocon approved in **U.S.**



2009-11

Process / Analytical
method development

2015-16

PK, Safety & Efficacy
Study

2016-18

Filing in U.S., EU

2018


Approved &
Launched in U.S.

At the Right Place at the Right Time


Biologics accounted for **11** of **Top 15** drugs by value in 2017*




40+ biosimilars
approved since
2006 in **EU**



11 biosimilars
approved since
2015 in **U.S.**




Differentiating to Lead



We have the 'Edge' to produce **innovative** and **affordable** biologics at a **scale** that can address **global** needs.

Making a Difference to People with Diabetes



Aim to support **‘1 in 5’** insulin-dependent people with **diabetes** the world over

Climbing the Learning Curve

Partnered with
Mylan for
biosimilars




Developed and
launched **2 novel
biologics** in India

Partnered with
Sandoz for
next-gen biosimilars

Path-breaking Novel Innovation



Supports **Insulin Tregopil** study in
Type 1 diabetes



A large investigator-led study established **Nimotuzumab**
as 'best-in-class' drug to treat head & neck cancer.
Results were presented at

ASCO[®]

AMERICAN SOCIETY OF CLINICAL ONCOLOGY
MAKING A **WORLD** OF DIFFERENCE IN CANCER CARE

Scale Up

- **India's largest** bio-manufacturing site in **Bengaluru**
- **Asia's largest** insulins manufacturing complex in **Malaysia**
- **Largest** fermentation based bulk-drug capacities for Statins & Immunosuppressants **globally**



Preparing for the Future

Commissioned our first solid-oral dosage forms facility in Bengaluru



Second antibodies facility coming up in Bengaluru


Overcoming Regulatory Challenges

Sterile DP Manufacturing Facility

- ✓ Received **EIR** (Establishment Inspection Report) from **U.S. FDA**
- ✓ Received **EU GMP** certification



Financial Highlights: FY18



Sustainability Programs & Social Responsibility

eLAJ Smart Clinics

- **10** clinics added in Karnataka
- **2.3 lakh** patient visits recorded in **FY18**
- **Jhalwar PHC** declared '**model**' PHC by Rajasthan Govt.

Cancer detection program

- **53,000** men and women screened for oral, breast and cervical cancers till date

Child malnutrition

- **460+** severely malnourished children benefited



Sustainability Programs & Social Responsibility

Hebbagodi Lake Revived: 34 acres



Before

Cleaning debris, garbage & weeds



Daily dosing of enzymes



After

Floating wetlands & submersible aerators



- **Garbage, sludge & weeds** removed
- **Inlets** cleaned, **bar screen** installed
- **Embankment** strengthened
- **Streetlights** installed
- **Children's park** built

- **Eco-friendly bioremediation process** deployed
- **Daily Dosing of Enzymes**
- **Submersible and Cascading aerators** installed
- **Floating wetlands** introduced

Social Responsibility: Skill Development



Focus on Developing Biotech Graduates into Industry Ready Talent

- **400** students have benefitted till date from the Academy
- **100%** placement record maintained by the Academy
- **>55%** students recruited by leading life science companies in India

Two New Programs Introduced:

- **Faculty Development Program (FDP)**
- **Clinical Development Program (CDP)**

Looking Ahead




- **Biosimilars** approvals to translate into accelerated revenues
- **Syngene** poised to do well
- **Small Molecules, Branded Formulations** to deliver positive performance
- Set for **sustainable long-term growth** led by all businesses



Thanks to Shareholders
for believing in us
and
supporting us!

THANK YOU



40th

Annual General Meeting

CHAIRPERSON'S SPEECH

Kiran Mazumdar-Shaw
Chairperson & Managing Director

July 27th, 2018
Biocon Research Centre

BSE: 532523 | NSE: BIOCON | REUTERS: BION.NS
| BLOOMBERG: BIOS IN | WWW.BIOCON.COM

Enduring
Edge

